|
GB201718856D0
|
|
Medicinal compositions for the treatment of inflammatory conditions and autoimmune diseases
|
|
GB201518063D0
|
|
Chrono-parenteral administration of high-dose melatonin to treat severe disrupted circadian rhythm in critically ill patients
|
|
US2017239217A1
|
|
Anhydrous liquid melatonin composition
|
|
BR112012011703A2
|
|
compound, pharmaceutical composition, and use of a compound
|
|
US2009035260A1
|
|
Enhanced nasal composition of active peptide
|
|
AU2008208865A1
|
|
Antiviral compounds
|
|
CN101622265A
|
|
Antiviral compounds
|
|
GR1006211B
|
|
Mixture of flavours for formulations containing iron.
|
|
EP2073835A1
|
|
Antimetastatic effect on human cell disorders
|
|
KR20070108064A
|
|
Mixture of flavours for formulations containing iron
|
|
KR20080030835A
|
|
Pharmaceutical composition
|
|
EP1968640A1
|
|
Compounds for use in treating abnormal cell proliferation, and methods of producing same
|
|
WO2006122905A2
|
|
A substantially water-free pressurised propellant mixture
|
|
EP1707192A2
|
|
Pharmaceutical composition
|
|
WO2005079747A1
|
|
Pharmaceutical preparation for the oral cavity
|
|
WO2005005057A1
|
|
Device for enhancing the performance of dispensers
|
|
AU2003238039A1
|
|
Nasal peptide pharmaceutical formulation
|
|
AU7777300A
|
|
Method and kit for performing serum or plasma sialic acid assays
|
|
KR20010058885A
|
|
Preparation of an antianemic complex
|
|
GR990100195A
|
|
Preparation of an anaemia-preventing complex
|
